Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Alliances entities : Eli lilly and company save search
Fauna Bio Announces Strategic Collaboration with Lilly to Discover Novel Obesity Targets Using Convergence™ AI Platform
Published: 2023-12-21 (Crawled : 15:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.21%
H: 0.63%
C: 0.1%
obesity collaboration platform
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego
Published: 2023-11-28 (Crawled : 21:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
ARE A | $116.45 -0.46% -0.12% 610K
|
Finance
|
| O: -0.19%
H: 3.05%
C: 2.77%
partnership
Redwire Announces First Spaceflight Mission for New Cutting-Edge Pharmaceutical Drug Development Lab, Partnering with Eli Lilly and Company to Expand Space Research to Study Heart Disease and Diabetes
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
drug disease company space research heart diabetes study
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
Published: 2023-09-22 (Crawled : 15:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -2.93%
H: 1.22%
C: 0.32%
jardiance fda disease kidney treatment
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors
Published: 2023-09-19 (Crawled : 13:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.06%
H: 1.19%
C: 0.58%
bbi-355 verzenio tumors collaboration trial agreement
Allen Institute for Immunology partners with Lilly to better understand autoimmune disease
Published: 2023-07-18 (Crawled : 18:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.04%
H: 1.43%
C: 0.95%
institute disease immunology
Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases
Published: 2023-05-16 (Crawled : 15:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.07%
H: 0.98%
C: 0.56%
genetic wholly collaboration neurological
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases
Published: 2023-04-27 (Crawled : 12:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 3.98%
H: 1.86%
C: -0.23%
zb-106 potential
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China
Published: 2023-01-17 (Crawled : 15:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.0%
H: 0.11%
C: -1.07%
therapeutics migraine china
Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases
Published: 2023-01-04 (Crawled : 14:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.1%
H: 0.68%
C: -0.42%
wholly collaboration
Lilly and ProQR to Expand RNA Editing CollaborationNew agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology
Published: 2022-12-22 (Crawled : 13:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.55%
PRQR | $1.92 -4.0% -4.17% 200K
|
Health Technology
|
| O: 64.85%
H: 13.97%
C: -0.74%
axiomer technology agreement
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
Published: 2022-08-25 (Crawled : 12:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.54%
H: 0.86%
C: 0.79%
ACRS | $1.23 0.82% 0.81% 560K
|
Health Technology
|
| O: 1.27%
H: 3.94%
C: 3.94%
patent license therapeutics agreement
Tempus Announces Sequencing Collaboration With Lilly to Expand Access to Genomic Testing
Published: 2022-06-09 (Crawled : 15:20) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.6%
H: 0.1%
C: -2.68%
collaboration genomic test
Iterative Scopes to Present Three Abstracts on Artificial Intelligence Applications for GI Endoscopy at DDW 2022
Published: 2022-05-19 (Crawled : 14:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -2.5%
H: 0.0%
C: -2.49%
endoscopy
FDA Approves Eli Lily's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant covid
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
Published: 2022-04-25 (Crawled : 12:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -3.29%
H: 2.58%
C: 2.31%
NEO | $13.68 -1.23% -1.24% 560K
|
Health Services
|
| O: -2.83%
H: 2.64%
C: 2.27%
partnership program cancer test
ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerPhase 2/3 study initiated in collaboration with Eli Lilly and Company
Published: 2022-03-02 (Crawled : 18:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALXO | $16.08 10.97% 9.89% 2M
|
Commercial Services
|
| O: 0.0%
H: 4.13%
C: 3.97%
aspen-06 treatment phase 2 phase 2/3 collaboration cancer initiated
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 15:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence
Published: 2022-02-16 (Crawled : 15:30) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.52%
H: 1.83%
C: 1.24%
risk cancer breast cancer
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
Published: 2022-02-15 (Crawled : 13:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.84%
H: 3.44%
C: 3.04%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 2.53%
H: 5.43%
C: 2.11%
license platform
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.